Company / SG&A Expense
Monte Rosa Therapeutics, Inc. SG&A Expense History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$35.2M
FY2024
5-year range
$4.0M / $35.2M
FY2020-FY2024
Trend
+9.8%
vs FY2023
Sector context
#175 of 213
Health Care
What the data says
Monte Rosa Therapeutics, Inc.'s sg&a expense of $35M is lower than 82% of companies in the Health Care sector (FY2024). SG&A Expense has increased for 4 consecutive years, from $4M in FY2020 to $35M in FY2024.
Based on SEC 10-K filings.
$35M in FY2024 with a 3-year CAGR of +30.8%.
Increased from $27M to $35M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +30.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 18% in Health CareTop 18% of 213This company $35.2M Sector average $722.3M
▼
-95.1% below sector average
Key checks
Key Insights
- Monte Rosa Therapeutics, Inc.'s sg&a expense has grown for 4 consecutive years.
- 3-year CAGR of +30.8%, indicating consistent growth.
- In FY2024, sg&a expense increased 9.8% year-over-year.
- Ranks #175 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $35.2M | +9.8% |
| FY2023 | $32.0M | +17.3% |
| FY2022 | $27.3M | +73.7% |
| FY2021 | $15.7M | +292.7% |
| FY2020 | $4.0M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026